Business Context and Reporting Period
Company: Basel Medical Group Ltd (Nasdaq: BMGL)
Reporting Period: June 10, 2026
Business: Medical clinic operator based in Singapore, incorporated in the British Virgin Islands.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate action regarding share structure.
Material Changes
- Reverse Share Split: The Board approved a 1-for-12 reverse share split effective June 22, 2026.
- Share Count Reduction: Outstanding shares will decrease from 18,785,750 to approximately 1,565,480.
- Compliance Driver: The action is intended to re-comply with Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1 per share.
- Trading Details: Shares will trade under the same symbol "BMGL" with a new CUSIP number (G0864B111).
- Fractional Shares: No fractional shares will be issued; shareholders will receive one whole share in lieu of fractional entitlements.
Guidance, Outlook, and Risks
Management Commentary: The split requires no shareholder approval or amendment to the articles of association under British Virgin Islands law.
Risks/Contingencies: The primary risk addressed is potential delisting due to failure to maintain the minimum bid price. The filing does not contain forward-looking financial guidance or discuss other operational risks.
Investor Verification Checklist
- Verify the effective trading date of June 22, 2026, for the split-adjusted shares.
- Confirm the new CUSIP number (G0864B111) with your brokerage to ensure proper account updates.
- Monitor the post-split bid price to ensure it meets the $1.00 Nasdaq minimum requirement.
- Review the exact number of shares held to understand the rounding impact on fractional share entitlements.